<DOC>
	<DOCNO>NCT01323517</DOCNO>
	<brief_summary>The purpose study see effect add systemic study drug , Ipilimumab , two standard chemotherapy drug , Melphalan Dactinomycin . The study drug Ipilimumab antibody normal protein find body , CTLA-4 . This protein normally allow immune system ( body 's natural defense system help fight infection ) use quiet immune response . The study drug work block protein allow immune system become active . This study investigate effect , combine ILI ( use two standard drug treat melanoma , Melphalan Dactinomycin ) , study drug , Ipilimumab advance Melanoma cancer .</brief_summary>
	<brief_title>Addition Ipilimumab ( MDX-010 ) To Isolated Limb Infusion ( ILI ) With Standard Melphalan Dactinomycin In The Treatment Advanced Unresectable Melanoma The Extremity</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Willing able give write informed consent . Histologic diagnosis melanoma transit metastasis Stage IIIB , IIIC , IV Required value initial laboratory test : WBC ≥ 2000/uL ANC ≥ 1000/uL Platelets ≥ 50 x 103/uL Hemoglobin ≥ 8 g/dL Creatinine ≤ 3.0 x ULN AST/ALT ≤ 2.5 x ULN Bilirubin ≤ 3.0 x ULN , ( except patient Gilbert 's Syndrome , must total bilirubin less 3.0 mg/dL ) No active chronic infection HIV , Hepatitis B , Hepatitis C. Karnofsky performance status ≥60 Men woman , ≥ 18 year age . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 8 week last dose investigational product , manner risk pregnancy minimize . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Postmenopause define : Amenorrhea ≥ 12 consecutive month without another cause , For woman irregular menstrual period take hormone replacement therapy ( HRT ) , document serum follicle stimulate hormone ( FSH ) level ≥ 35 mIU/mL . Women use oral contraceptive , hormonal contraceptive ( vaginal product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy , practice abstinence partner sterile ( eg , vasectomy ) consider childbearing potential . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour start ipilimumab . Any malignancy form patient diseasefree less 2 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer carcinoma situ cervix . Autoimmune disease : Patients history inflammatory bowel disease exclude study , patient history symptomatic disease ( eg , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ eg , Wegener 's Granulomatosis ] ) ; motor neuropathy consider autoimmune origin ( e.g . GuillainBarre Syndrome ) . Any underlying medical psychiatric condition , opinion investigator make administration ipilimumab hazardous obscure interpretation AEs , condition associate frequent diarrhea . Patients underlying heart condition deem ineligible surgery cardiology consult Any history prior treatment ipilimumab prior CD137 agonist CTLA4 inhibitor agonist . Concomitant therapy following : IL2 , interferon , nonstudy immunotherapy regimen ; immunosuppressive agent ; investigation therapy ; chronic use systemic corticosteroid . Women childbearing potential ( WOCBP ) , : unwilling unable use acceptable method contraception avoid pregnancy entire study period least 8 week cessation study drug , positive pregnancy test baseline , pregnant breastfeeding . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( eg , infectious ) illness . Persons reproductive potential must agree use adequate method contraception throughout treatment least 8 week ipilimumab stop . Sexually active WOCBP must use effective method birth control course study , manner risk failure minimize . Before study enrollment , WOCBP must advise importance avoid pregnancy study participation potential risk factor unintentional pregnancy . All WOCBP MUST negative pregnancy test first receive ipilimumab . If pregnancy test positive , patient must receive ipilimumab must enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>skin</keyword>
	<keyword>DACTINOMYCIN</keyword>
	<keyword>MDX-010 ( Ipilimumab )</keyword>
	<keyword>MELPHALAN</keyword>
	<keyword>Isolated Limb Infusion</keyword>
	<keyword>10-101</keyword>
</DOC>